Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Biliary Tract Neoplasms 2Advanced or Metastatic Solid Tumors 2Thymoma 1Solid Tumor 1Sarcoma 1Piebaldism 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Carboplatin 121pembrolizumab 119Pemetrexed 102Cisplatin 76Paclitaxel 56osimertinib 52Nivolumab 50Docetaxel 50durvalumab 47Specimen Handling 37Gemcitabine 34Magnetic Resonance Spectroscopy 33Radiosurgery 27Cetuximab 26130-nm albumin-bound paclitaxel 26atezolizumab 25Radiotherapy 20Ipilimumab 19Drug Therapy 19Bevacizumab 19cemiplimab 17amivantamab 17Taxes 16Ramucirumab 13alectinib 12tislelizumab 11lazertinib 11Leucovorin 11Fluorouracil 11Radiation 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × envafolimab × 90 days × Clear all
NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡